Answers are grounded in this paper and cite their sources.
Background Thiazole scaffolds are considered as a promising class of compounds in anticancer drug development because of their structural diversity, and their ability to bind to a variety of oncogenic targets; however, their pharmacokinetics and drug-like properties are dependent on the structural modifications. This review aims to present a scaffold- and mechanism-based assessment of various thiazole-containing anticancer agents which have been developed and investigated in the past few decades. Methods To identify the studies reporting anticancer activity, structure-activity relationship (SAR) studies, mechanistic investigations, and computational analysis of thiazole-based derivatives, a structured literature survey was conducted using PubMed, Scopus database, Web of Science, and Google Scholar databases with predefined relevance criteria. It systematically combines position-specific structural variations at C-2, C-4, and C-5 positions of thiazole nucleus with biological activity to emphasize the effect of each modification, including electronic distribution, steric effects, linker flexibility, scaffold hybridization and ring fusion, on target selectivity and cytotoxic potency. Results The biological activity of DNA-interacting and apoptosis-inducing thiazole chemotypes was boosted by electron-donating and moderate electron-withdrawing substituents that provided increased binding affinity to kinases and tubulin via hydrophobic and halogen-bond interactions, while excessive steric bulk resulted in decreased biological activity due to poor target fit. Some of the derivatives had submicromolar to low micromolar cytotoxicity against various cancer cell lines, including those that exhibited efficacy similar to that of anticancer drugs under experimental conditions. These compounds inhibited key oncogenic pathways such as EGFR, VEGFR-2, CDK2, PI3K/AKT/mTOR, MAPK, SMYD3, tubulin polymerization, induced apoptosis, mitochondrial dysfunction, DNA damage, topoisomerase inhibition, and cell-cycle arrest at G0/G1, S and G2/M phases. A few thiazole hybrids also had multidrug resistance (MDR) reversal activity by targeting the pathways of efflux and multitarget signaling. SAR and mechanistic insights were supported by molecular docking, molecular dynamics, QSAR modeling, and pharmacophore modeling and ADMET prediction. In vivo xenograft studies and clinically approved thiazole containing drugs highlight the translational potential of thiazole pharmacophore. Conclusions Based on the available evidence, the future rationalization of thiazole-based anticancer therapeutics seems to be best served by rational hybridization strategies, optimization of physicochemical properties and kinase selectivity, and thorough ADMET/selectivity profiling.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: